Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which steroid works best for COPD attacks? major trial aims to find out

NCT ID NCT06892210

Disease control Sponsor: Copenhagen Respiratory Research Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two steroids, hydrocortisone and prednisolone, in 2000 adults over 40 with COPD flare-ups. The goal is to see which one reduces hospital readmissions and deaths within 30 days. Participants are randomly assigned to one of the two treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hydrocortisone and prednisolone (corticosteroids)
What this could lead to
If it works, this could identify which steroid works best for COPD flare-ups, potentially reducing hospital readmissions and deaths.
What could go wrong
This is a late-stage trial but compares two similar drugs already in use, so a dramatic breakthrough is unlikely. Results may show no meaningful difference.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Nov 2030

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥40 years * Chronic obstructive pulmonary disease with acute exacerbation, unspecified: ICDJ44 Exclusion Criteria: * All diagnoses that would merit treatment with a specific corticosteroid * Pregnant or breastfeeding women * Active tuberculosis or invasive fungal infection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease (COPD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic obstructive pulmonary disease (COPD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    14 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Amager Hospital

    RECRUITING

    Copenhagen, Copenhagen City, 2300, Denmark

  • Bispebjerg Hospital

    RECRUITING

    Copenhagen, Copenhagen City, 2400, Denmark

  • Bornholm Hospital

    RECRUITING

    Rønne, Bornholm, 3700, Denmark

  • Frederiksberg Hospital

    RECRUITING

    Frederiksberg, Copenhagen City, 2000, Denmark

  • Gentofte Hospital

    RECRUITING

    Hellerup, Copenhagen City, 2900, Denmark

  • Herlev Hospital

    RECRUITING

    Herlev, Copnhagen Surroundings, 2730, Denmark

  • Holbæk Sygehus

    RECRUITING

    Holbæk, Region Sjælland, 4300, Denmark

  • Hvidovre Hospital

    RECRUITING

    Hvidovre, Copnhagen Surroundings, 2650, Denmark

  • Nordsjællands Hospital

    RECRUITING

    Hillerød, North Zealand, 3400, Denmark

  • Næstved Sygehus

    RECRUITING

    Næstved, Region Sjælland, 4700, Denmark

  • Ringsted Sygehus

    RECRUITING

    Ringsted, Region Sjælland, 4100, Denmark

  • Slagelse Sygehus

    RECRUITING

    Slagelse, Region Sjælland, 4200, Denmark

  • University Hospital of Region Zealand, Køge

    RECRUITING

    Køge, Region Sjælland, 4600, Denmark

  • University Hospital of Region Zealand, Roskilde

    RECRUITING

    Roskilde, Region Sjælland, 4000, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.